Tamoxifen Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Conditions:   Breast Cancer;   Early-stage Breast Cancer;   High Risk Breast Carcinoma Interventions:   Drug: Abemaciclib;   Drug: Tamoxifen;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane;   Drug: LHRH Agonist Sponsors:   Dana-Farber Cancer Institute;   Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 21, 2023 Category: Research Source Type: clinical trials

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Condition:   Breast Cancer, Early Breast Cancer Interventions:   Drug: Camizestrant;   Drug: Tamoxifen;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane;   Drug: Abemaciclib Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials